Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Mizuho Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $19

Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.
byBenzinga Newsdesk
July 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Mizuho analyst Graig Suvannavejh initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $19.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Tilray Ramps Up Its Cannabis Portfolio In Canada, Wins International Spirits Competition

By Jelena Martinovic
June 6, 10:39 AM
Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) announced on Thursday the launch of 'Purple Churro,' by Redecan cannabis.The new sativa offers "a sweet, indulgent experience with a potent twist and boasting THC levels," the Canadian cannabis giant said in a press release.Purple Churro is a cross of Cinnamon Horchata and Apples & Bananas, featuring a blend of sweet vanilla and cinnamon-tasting notes.In the meantime, the company's liquor business is celebrating two wins at the 15th annual New York International Spirits Competition. Tilray's subsidiary Breckenridge Distillery was a winner at Colorado American Blended Whiskey Distillery of the Year and Double Gold for Breckenridge Port Cask Finish.

TLRY